223 related articles for article (PubMed ID: 32751071)
21. Increased cytotoxicity and decreased in vivo toxicity of FdUMP[10] relative to 5-FU.
Liu J; Skradis A; Kolar C; Kolath J; Anderson J; Lawson T; Talmadge J; Gmeiner WH
Nucleosides Nucleotides; 1999 Aug; 18(8):1789-802. PubMed ID: 10478484
[TBL] [Abstract][Full Text] [Related]
22. Correlations between thymidylate synthase expression and chemosensitivity to 5-fluorouracil, cell proliferation and clinical outcome in head and neck squamous cell carcinoma.
Yasumatsu R; Nakashima T; Uryu H; Ayada T; Wakasaki T; Kogo R; Masuda M; Fukushima M; Komune S
Chemotherapy; 2009; 55(1):36-41. PubMed ID: 19023200
[TBL] [Abstract][Full Text] [Related]
23. Biochemical mechanisms of interferon modulation of 5-fluorouracil activity in colon cancer cells.
van der Wilt CL; Smid K; Aherne GW; Noordhuis P; Peters GJ
Eur J Cancer; 1997 Mar; 33(3):471-8. PubMed ID: 9155534
[TBL] [Abstract][Full Text] [Related]
24. Patterns of elevation of plasma 2'-deoxyuridine, a surrogate marker of thymidylate synthase (TS) inhibition, after administration of two different schedules of 5-fluorouracil and the specific TS inhibitors raltitrexed (Tomudex) and ZD9331.
Ford HE; Mitchell F; Cunningham D; Farrugia DC; Hill ME; Rees C; Calvert AH; Judson IR; Jackman AL
Clin Cancer Res; 2002 Jan; 8(1):103-9. PubMed ID: 11801545
[TBL] [Abstract][Full Text] [Related]
25. [Modulation of the biochemical effect of 5-fluorouracil (5-FU) by leucovorin measured by thymidylate synthase activity and nucleoside incorporation into DNA].
Kau B; Rieger M; Sauer H
Onkologie; 1990 Dec; 13(6):453-7. PubMed ID: 2092282
[TBL] [Abstract][Full Text] [Related]
26. Review of 5-FU resistance mechanisms in colorectal cancer: clinical significance of attenuated on-target effects.
Gmeiner WH; Okechukwu CC
Cancer Drug Resist; 2023; 6(2):257-272. PubMed ID: 37457133
[TBL] [Abstract][Full Text] [Related]
27. Thymidine kinase, thymidylate synthase, and dihydropyrimidine dehydrogenase profiles of cell lines of the National Cancer Institute's Anticancer Drug Screen.
Grem JL; Danenberg KD; Behan K; Parr A; Young L; Danenberg PV; Nguyen D; Drake J; Monks A; Allegra CJ
Clin Cancer Res; 2001 Apr; 7(4):999-1009. PubMed ID: 11309351
[TBL] [Abstract][Full Text] [Related]
28. Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA levels in thymoma.
Sasaki H; Fukai I; Kiriyama M; Kaji M; Yano M; Yamakawa Y; Fujii Y
Surg Today; 2003; 33(2):83-8. PubMed ID: 12616366
[TBL] [Abstract][Full Text] [Related]
29. Effects on DNA and RNA after the administration of two different schedules of 5-fluorouracil in colorectal cancer patients.
Hoshino S; Yamashita Y; Maekawa T; Shirakusa T
Cancer Chemother Pharmacol; 2005 Dec; 56(6):648-52. PubMed ID: 15959779
[TBL] [Abstract][Full Text] [Related]
30. [The correlation between thymidylate synthase expression and cytotoxicity of 5-fluorouracil in human cancer cell lines: study using polyclonal antibody against recombinant human thymidylate synthase].
Okabe H; Tsujimoto H; Fukushima M
Gan To Kagaku Ryoho; 1997 Apr; 24(6):705-12. PubMed ID: 9126308
[TBL] [Abstract][Full Text] [Related]
31. Synergistic efficacy of 3n-butyrate and 5-fluorouracil in human colorectal cancer xenografts via modulation of DNA synthesis.
Bras-Gonçalves RA; Pocard M; Formento JL; Poirson-Bichat F; De Pinieux G; Pandrea I; Arvelo F; Ronco G; Villa P; Coquelle A; Milano G; Lesuffleur T; Dutrillaux B; Poupon MF
Gastroenterology; 2001 Mar; 120(4):874-88. PubMed ID: 11231942
[TBL] [Abstract][Full Text] [Related]
32. 5-fluorouracil and dihydropyrimidine dehydrogenase.
Kubota T
Int J Clin Oncol; 2003 Jun; 8(3):127-31. PubMed ID: 12851835
[TBL] [Abstract][Full Text] [Related]
33. 5-Fluorouracil incorporated into DNA is excised by the Smug1 DNA glycosylase to reduce drug cytotoxicity.
An Q; Robins P; Lindahl T; Barnes DE
Cancer Res; 2007 Feb; 67(3):940-5. PubMed ID: 17283124
[TBL] [Abstract][Full Text] [Related]
34. Intratumoral induction of thymidylate synthase mRNA by 5-FU in colorectal cancer patients: association with survival.
Tanaka-Nozaki M; Tajiri T; Tanaka N; Furukawa K; Takasaki H; Yoshimura K; Suzuki H; Naito Z; Sugizaki Y; Merk HF; Blömeke B; Kato S
Oncol Rep; 2003; 10(5):1425-9. PubMed ID: 12883718
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of FdUMP[10] in treatment of HT-29 human colon cancer xenografts.
Liu C; Willingham M; Liu J; Gmeiner WH
Int J Oncol; 2002 Aug; 21(2):303-8. PubMed ID: 12118325
[TBL] [Abstract][Full Text] [Related]
36. The multidrug resistance protein 5 (ABCC5) confers resistance to 5-fluorouracil and transports its monophosphorylated metabolites.
Pratt S; Shepard RL; Kandasamy RA; Johnston PA; Perry W; Dantzig AH
Mol Cancer Ther; 2005 May; 4(5):855-63. PubMed ID: 15897250
[TBL] [Abstract][Full Text] [Related]
37. Determinants of trifluorothymidine sensitivity and metabolism in colon and lung cancer cells.
Temmink OH; de Bruin M; Comijn EM; Fukushima M; Peters GJ
Anticancer Drugs; 2005 Mar; 16(3):285-92. PubMed ID: 15711180
[TBL] [Abstract][Full Text] [Related]
38. Fluorouracil and the new oral fluorinated pyrimidines.
Kuhn JG
Ann Pharmacother; 2001 Feb; 35(2):217-27. PubMed ID: 11215843
[TBL] [Abstract][Full Text] [Related]
39. Creation and characterization of 5-fluorodeoxyuridine-resistant Arg50 loop mutants of human thymidylate synthase.
Landis DM; Heindel CC; Loeb LA
Cancer Res; 2001 Jan; 61(2):666-72. PubMed ID: 11212266
[TBL] [Abstract][Full Text] [Related]
40. Modulation of 5-fluorouracil by 5-ethyl-2'-deoxyuridine on cell lines expressing different dihydropyrimidine dehydrogenase activities.
Katona C; Tímár F; Jeney A; Fischel JL; Milano G; Pandi E; Kralovánszky J
Anticancer Drugs; 1999 Jul; 10(6):561-7. PubMed ID: 10885904
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
